[go: up one dir, main page]

HUP9900019A3 - Use of human cb2 receptor agonist indole derivatives for preparing immunomodulating drugs, new cb2 receptor agonist compounds and pharmaceutical compositions containing them - Google Patents

Use of human cb2 receptor agonist indole derivatives for preparing immunomodulating drugs, new cb2 receptor agonist compounds and pharmaceutical compositions containing them

Info

Publication number
HUP9900019A3
HUP9900019A3 HU9900019A HUP9900019A HUP9900019A3 HU P9900019 A3 HUP9900019 A3 HU P9900019A3 HU 9900019 A HU9900019 A HU 9900019A HU P9900019 A HUP9900019 A HU P9900019A HU P9900019 A3 HUP9900019 A3 HU P9900019A3
Authority
HU
Hungary
Prior art keywords
receptor agonist
preparing
human
new
pharmaceutical compositions
Prior art date
Application number
HU9900019A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HUP9900019A2 publication Critical patent/HUP9900019A2/hu
Publication of HUP9900019A3 publication Critical patent/HUP9900019A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HU9900019A 1995-06-21 1996-06-20 Use of human cb2 receptor agonist indole derivatives for preparing immunomodulating drugs, new cb2 receptor agonist compounds and pharmaceutical compositions containing them HUP9900019A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9507438A FR2735774B1 (fr) 1995-06-21 1995-06-21 Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
HUP9900019A2 HUP9900019A2 (hu) 1999-10-28
HUP9900019A3 true HUP9900019A3 (en) 2001-03-28

Family

ID=9480236

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900019A HUP9900019A3 (en) 1995-06-21 1996-06-20 Use of human cb2 receptor agonist indole derivatives for preparing immunomodulating drugs, new cb2 receptor agonist compounds and pharmaceutical compositions containing them

Country Status (29)

Country Link
US (1) US6013648A (hu)
EP (1) EP0833818B1 (hu)
JP (1) JP3417566B2 (hu)
KR (1) KR19990028272A (hu)
CN (1) CN1150166C (hu)
AT (1) ATE207054T1 (hu)
AU (1) AU717858B2 (hu)
BR (1) BR9608640A (hu)
CA (1) CA2225379A1 (hu)
CZ (1) CZ292630B6 (hu)
DE (1) DE69616056T2 (hu)
DK (1) DK0833818T3 (hu)
EE (1) EE9700345A (hu)
ES (1) ES2165986T3 (hu)
FR (1) FR2735774B1 (hu)
HU (1) HUP9900019A3 (hu)
IL (1) IL122637A0 (hu)
IS (1) IS4637A (hu)
MX (1) MX9710251A (hu)
NO (1) NO975989L (hu)
NZ (1) NZ312161A (hu)
PL (1) PL185598B1 (hu)
PT (1) PT833818E (hu)
RU (1) RU2200736C2 (hu)
SI (1) SI0833818T1 (hu)
SK (1) SK283660B6 (hu)
TR (1) TR199701660T1 (hu)
UA (1) UA67717C2 (hu)
WO (1) WO1997000860A1 (hu)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
WO1999057107A2 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
EP1075470B1 (en) 1998-05-04 2003-08-13 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
DE19837627A1 (de) * 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
GB9923314D0 (en) * 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
EP1702617A1 (en) * 1999-10-18 2006-09-20 The University Of Connecticut Cannabimimetic indole derivatives
WO2001028329A1 (en) 1999-10-18 2001-04-26 University Of Connecticut Peripheral cannabinoid receptor (cb2) selective ligands
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US8084467B2 (en) 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
MXPA02005101A (es) * 1999-10-18 2003-09-25 Alexipharma Inc Derivados de indol canabimimeticos.
US7741365B2 (en) 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP2003534298A (ja) * 2000-05-23 2003-11-18 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 咳の新規治療法
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
FR2814678B1 (fr) * 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US7329651B2 (en) 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
ATE478670T1 (de) 2001-01-29 2010-09-15 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
EP1414775B1 (en) 2001-07-13 2012-12-19 The University of Connecticut Bicyclic cannabinoid
WO2003007901A1 (en) * 2001-07-18 2003-01-30 Unilever Plc Hair and/or scalp treatment compositions
CA2464333C (en) 2001-10-26 2011-07-26 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
HUP0401924A3 (en) * 2001-11-14 2009-07-28 Schering Corp Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them
TW200407110A (en) * 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
CA2468794A1 (en) * 2001-12-07 2003-06-19 Virginia Commonwealth University Treatment of neoplasia
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US6933316B2 (en) * 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
WO2003061699A1 (en) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedies for allergic diseases
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
ATE340792T1 (de) 2002-02-01 2006-10-15 Hoffmann La Roche Substituierte indole als alpha-1 agonisten
DE60329981D1 (de) 2002-02-19 2009-12-24 Shionogi & Co Antipruriginosa
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
FR2839718B1 (fr) * 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
US7217732B2 (en) * 2002-06-19 2007-05-15 Schering Corporation Cannabinoid receptor agonists
WO2004017922A2 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
CA2506895A1 (en) 2002-11-25 2004-06-10 Schering Corporation Cannabinoid receptor ligands
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP1644335A4 (en) 2003-07-11 2008-06-04 Bristol Myers Squibb Co TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
ATE444066T1 (de) * 2004-06-22 2009-10-15 Schering Corp Liganden für den cannabinoidrezeptoren
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7560481B2 (en) 2004-12-21 2009-07-14 Abbott Laboratories Indoles are cannabinoid receptor ligands
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
FR2893615B1 (fr) 2005-11-18 2008-03-07 Sanofi Aventis Sa Derives de 3-acylindole, leur preparation et leur application en therapeutique
EP2024349B1 (en) 2006-05-31 2017-08-02 AbbVie Inc. Compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CA2681586A1 (en) 2007-03-28 2008-10-09 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
MX2009012374A (es) 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
FR2933697B1 (fr) 2008-07-11 2010-08-13 Sanofi Aventis Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
RU2011115087A (ru) 2008-09-16 2012-10-27 Эбботт Лэборетриз (Us) Замещенные бензамиды в качестве лигандов каннабиноидного рецептора
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
US20120277296A1 (en) 2009-07-23 2012-11-01 Sophie Lotersztajn Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
FR2950055A1 (fr) 2009-09-17 2011-03-18 Sanofi Aventis Derives de 3-amino-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique
WO2012024670A2 (en) * 2010-08-20 2012-02-23 University Of Washington Through Its Center For Commercialization Composition and methods for treating glioblastoma
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
US9416103B2 (en) * 2012-01-09 2016-08-16 The Board Of Trustees Of The University Of Arkansas Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases
US9656981B2 (en) 2012-07-20 2017-05-23 The Regents Of The University Of California Peripherally-acting cannabinoid receptor agonists for chronic pain
KR20150102511A (ko) * 2014-02-28 2015-09-07 주식회사 아세아텍 베일러용 드로우
CZ2014985A3 (cs) * 2014-12-31 2016-03-09 Vysoká škola chemicko- technologická v Praze Derivát syntetického kanabinoidu, způsob jeho přípravy a použití
CZ306547B6 (cs) * 2014-12-31 2017-03-01 Vysoká škola chemicko - technologická v Praze Derivát syntetického kanabinoidu, způsob jeho přípravy a použití
US20190133995A1 (en) * 2016-04-29 2019-05-09 Corbus Pharmaceuticals, Inc. Methods for the treatment of infection
CN108794379A (zh) * 2017-04-26 2018-11-13 华东师范大学 1h-吲哚-2-甲酰胺衍生物及其制备方法和应用
WO2019144126A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
JP2023512821A (ja) 2020-02-04 2023-03-29 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO77049A2 (ro) * 1980-08-08 1981-06-22 Institutul De Cercetari Chimico-Farmaceutice,Ro Derivati de 2-metil-3-etilindol si procedeu de preparare a acestora
RO90049A2 (ro) * 1984-12-25 1986-08-30 Centrala Industriala De Medicamente Cosmetice,Coloranti Si Lacuri,Ro Procedeu de preparare a clorhidratului hidrat de 1-(p-clorbenzoil)3-/2-(di-n-propilamino) etil/5-metoxi-2-metilindol
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
US5081122A (en) * 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) * 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
NO975989L (no) 1998-02-19
AU6363296A (en) 1997-01-22
PL185598B1 (pl) 2003-06-30
JP3417566B2 (ja) 2003-06-16
AU717858B2 (en) 2000-04-06
BR9608640A (pt) 1999-05-18
HK1005093A1 (en) 1998-12-24
US6013648A (en) 2000-01-11
IS4637A (is) 1997-12-19
DK0833818T3 (da) 2002-02-11
IL122637A0 (en) 1998-08-16
NO975989D0 (no) 1997-12-19
CA2225379A1 (en) 1997-01-09
CZ414397A3 (cs) 1998-07-15
EE9700345A (et) 1998-06-15
MX9710251A (es) 1998-03-31
HUP9900019A2 (hu) 1999-10-28
CN1192732A (zh) 1998-09-09
KR19990028272A (ko) 1999-04-15
DE69616056T2 (de) 2002-06-20
CN1150166C (zh) 2004-05-19
FR2735774A1 (fr) 1996-12-27
FR2735774B1 (fr) 1997-09-12
PT833818E (pt) 2002-04-29
UA67717C2 (en) 2004-07-15
ES2165986T3 (es) 2002-04-01
DE69616056D1 (de) 2001-11-22
SK283660B6 (sk) 2003-11-04
SI0833818T1 (en) 2002-04-30
ATE207054T1 (de) 2001-11-15
CZ292630B6 (cs) 2003-11-12
WO1997000860A1 (fr) 1997-01-09
PL324185A1 (en) 1998-05-11
NZ312161A (en) 2000-08-25
EP0833818A1 (fr) 1998-04-08
RU2200736C2 (ru) 2003-03-20
JPH11507937A (ja) 1999-07-13
SK173597A3 (en) 1998-11-04
TR199701660T1 (xx) 1998-04-21
EP0833818B1 (fr) 2001-10-17

Similar Documents

Publication Publication Date Title
HUP9900019A3 (en) Use of human cb2 receptor agonist indole derivatives for preparing immunomodulating drugs, new cb2 receptor agonist compounds and pharmaceutical compositions containing them
NZ301265A (en) Indole derivatives as 5ht receptor antagonists, preparation and pharmaceutical compositions thereof
HUP9701714A3 (en) Indole derivatives neuropeptide y receptor antagonists, use thereof and pharmaceutical compositions containing these compounds
HUP9901244A3 (en) 3-pyrazolecarboxamide derivatives having cannabinoid receptor affinity, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9901296A3 (en) Substituted piperidine derivatives as nmda receptor antagonists and pharmaceutical compositions containing them
HUP9901245A3 (en) Indole derivatives useful as endothelin receptor antagonists, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9603298A3 (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions
IL131818A (en) Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and solvates and their preparation
ZA98691B (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
HUP0004301A3 (en) Use of indole derivatives for preparing pharmaceutical compositions for antagonising an mcp-1 mediased effect
HUP9901096A3 (en) Indole derivatives, preparation and use thereof, pharmaceutical composition containing these compounds
HUP0002830A3 (en) Indole and 2,3-dihydroindole derivatives, their preparation, use, and pharmaceutical compositions containing them
AU7052698A (en) Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates
HUP0105079A3 (en) Indole derivatives and their use as mcp-1 antagonists, process for preparation of the compounds and medicaments containing them
SI0918059T1 (en) Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them
IL122705A (en) 2-(4-Susbstituted)-benzylamino-2-methyl-propanamide derivatives their preparation and pharmaceutical compositions containing them
IL117331A0 (en) Indole derivatives their preparation and pharmaceutical compositions containing them
HUP0203603A3 (en) Novel il-8 receptor antagonist indole derivatives and pharmaceutical compositions containing them
HUP9901680A3 (en) Use of piperazin-, piperidin- or hexahidropiridazin derivatives for the preparation of pharmaceutical compositions, new piperazin derivatives and pharmaceutical compositions containing these compounds
HUP9800631A3 (en) 4-aminotetrahydrobenzisoxazole or -isothiazole derivatives, pharmaceutical compositions containing them and their use for the preparation of pharmaceutical compositions
HUP9802568A3 (en) Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists and pharmaceutical compositions containing them
IL122158A (en) 3-substituted bicyclic thiazole derivatives having 5-ht receptor affinity their preparation and pharmaceutical compositions containing them
HUP0001873A3 (en) Amidino-1,4-benzoxazepine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP9600333A2 (en) Azole derivatives as adhesive receptor antagonists, pharmaceutical compositions containing the same and process for their preparation
HUP0003104A3 (en) Amino-spiropiperidin-quinazoline derivatives, their use, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees